Solid Focal Liver Lesions: Dynamic and Late Enhancement Patterns with the Dual Phase Contrast Agent Gadobenate Dimeglumine

详细信息    查看全文

• 作者：Luigi Grazioli (1) (5)
  Maria Pia Bondioni (1)
  Niccolò Faccioli (2)
  Sebastiana Gambarini (1)
  Rita Tinti (1)
  Günther Schneider (3)
  Miles Kirchin (4)
  
• 关键词：contrast media ; liver ; magnetic resonance imaging ; meglumine
• 刊名：Journal of Gastrointestinal Cancer
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：41
• 期：4
• 页码：221-232
• 全文大小：1047KB
• 参考文献：1. Spinazzi A, Lorusso V, Pirovano G, Taroni P, Kirchin M, Davies A. MultiHance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol. 1998;5:S86-. CrossRef
  2. Kirchin MA, Pirovano G, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol. 1998;33:798-09. CrossRef
  3. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine. Acad Radiol. 1999;6:282-1. CrossRef
  4. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997;32:780-6. CrossRef
  5. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, Siegler P, von Der Lieth CW, Frank M, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol. 2006;41:222-. CrossRef
  6. de Ha?n C, Cabrini M, Akhnana L, Ratti D, Calabi L, Gozzini L. Gadobenate dimeglumine 0.5M solution for injection (MultiHance?): pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr. 1999;23 Suppl 1:S161-.
  7. Pintaske J, Martirosian P, Graf H, Erb G, Lodemann KP, Claussen CD, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol. 2006;41:213-1. Erratum Invest Radiol 2006; 41:859. CrossRef
  8. Schneider G, Maas R, Schultze Kool L, Rummeny E, Gehl HB, Lodemann K, et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol. 2003;38:85-4. CrossRef
  9. Kuwatsuru R, Kadoya M, Ohtomo K, et al. Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for MR imaging of liver tumors. Invest Radiol. 2001;36:632-1. CrossRef
  10. Caudana R, Morana G, Pirovano G, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA) - preliminary results of phase II clinical application. Radiology. 1996;199:513-0.
  11. Petersein J, Spinazzi A, Giovagnoni A, et al. Evaluation of the efficacy of gadobenate dimeglumine in MR imaging of focal liver lesions: a multicenter phase III clinical study. Radiology. 2000;215:727-6.
  12. Pirovano G, Vanzulli A, Marti-Bonmati L, et al. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. AJR Am J Roentgenol. 2000;175:1111-0.
  13. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol. 2000;35:25-4. CrossRef
  14. Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: morphological and functional information from MR imaging with gadobenate dimeglumine. Radiology. 2001;221:731-. CrossRef
  15. Grazioli L, Morana G, Kirchin MA, et al. MR Imaging of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (Ferumoxides): an intra-individual comparison. J Magn Reson Imaging. 2003;17:593-02. CrossRef
  16. Kim YK, Lee JM, Kim CS. Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol. 2004;14:5-3. CrossRef
  17. Kim YK, Kim CS, Lee YH, Kwak HS, Lee JM. Comparison of superparamagnetic iron oxide-enhanced and gadobenate dimeglumine-enhanced dynamic MRI for detection of small hepatocellular carcinomas. AJR Am J Roentgenol. 2004;182:1217-3.
  18. Kim YK, Lee JM, Kim CS, Chung GH, Kim CY, Kim IH. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol. 2005;15:220-. CrossRef
  19. Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology. 2005;236:166-7. CrossRef
  20. Wanless I, Mawdsley C, Adams R, et al. On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology. 1985;5:1194-00. CrossRef
  21. Cherqui D, Rahmouni A, Charlotte F, et al. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology. 1995;22:1674-1. CrossRef
  22. Labrune P, Trioche P, Duvaltier I, Chevalier P, Odièvre M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr. 1997;24:276-. Review. CrossRef
  23. Leese T, Farges O, Bismuth H. Liver cell adenomas. A 12-year surgical experience from a specialist hepato-biliary unit. Ann Surg. 1988;208:558-4. CrossRef
  24. Molina EG, Schiff ER. Benign solid lesion of the liver, chapter 53. In: Schiff’s. Diseases of the liver (8th edition) Vol.II. Lippincott-Raven 1999,53, page 1254-1257.
  25. Arrive L, Flejou JF, Vilgrain V, et al. Hepatic adenoma: MR findings in 51 pathologically proved lesions. Radiology. 1994;193:507-2.
  26. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990;11:787-7. Review. CrossRef
  27. Wanless IR. Noncirrhotic portal hypertension: recent concepts. Prog Liver Dis. 1996;14:265-8.
  28. Arvanitaki M, Adler M. Nodular regenerative hyperplasia of the liver. A review of 14 cases. Hepatogastroenterology. 2001;48:1425-.
  29. Brancatelli G, Federle MP, Grazioli L, et al. Large regenerative nodules in Budd-Chiari syndrome and other vascular disorders of the liver: CT and MR imaging findings with clinico-pathologic correlation. AJR Am J Roentgenol. 2002;178:877-3.
  30. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-0. CrossRef
  31. Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Human Pathol. 1991;22:172-. CrossRef
  32. Choi BI, Takayasu K, Han MC. Small hepatocellular carcinomas and associated nodular lesions of the liver: pathology, pathogenesis, and imaging findings. AJR Am J Roentgenol. 1993;160:1177-7.
  33. Noguchi S, Yamamoto R, Tatsuta M, et al. Cell features and patterns in fine-needle aspirates of hepatocellular carcinoma. Cancer. 1986;58:321-. CrossRef
  34. Manfredi R, Maresca G, Baron R, et al. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging. 1999;9:704-0. CrossRef
  35. Craig JR, Peters RL, Edmonson HA. Tumors of the liver and intrahepatic bile ducts: atlas of tumor pathology. Washington DC: Armed Forces Institute of Pathology; 1989.
  36. Maetani Y, Itoh K, Watanabe C, et al. MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. AJR Am J Roentgenol. 2001;176:1499-07.
  37. Vilgrain V, Van Beers BE, Flejou JF, et al. Intrahepatic cholangiocarcinoma: MRI and pathologic correlation in 14 patients. J Comput Assist Tomogr. 1997;21:59-5. CrossRef
  38. Murakami T, Nakamura H, Tsuda K, et al. Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: pathologic correlation study. J Magn Reson Imaging. 1995;5:165-0. CrossRef
  39. Zhang Y, Uchida M, Abe T, et al. Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI. J Comput Assist Tomogr. 1999;23:670-. CrossRef
  40. Ohsawa M, Aozasa K, Horiuchi K, et al. Malignant lymphoma of the liver. Dig Dis Sci. 1992;37:1105-. CrossRef
  41. Jaffe ES. Malignant lymphoma: pathology of hepatic involvement. Semin Liver Dis. 1987;7:257-8. CrossRef
  42. Bartolozzi C, Cioni D, Donati F, et al. Focal liver lesions: MR imaging-pathologic correlation. Eur Radiol. 2001;11:1374-8. CrossRef
  43. Goodman ZD. Nonparenchymal and metastatic malignant tumors of the liver. In: Haubrich WS, Schaffner F, Berk JE, editors. Bockus Gastroenterology. Philadelphia: WB Saunders; 1995. p. 2488-00.
  44. Larson RE, Semelka RC, Bagley AS, Molina PL, Brown ED, Lee JK. Hypervascular malignant liver lesions: comparison of various MR imaging pulse sequences and dynamic CT. Radiology. 1994;192:393-.
  45. Ferrucci JT. Liver tumor imaging. Current concepts. Radiol Clin North Am. 1994;32:39-4.
  46. Lewis KH, Chezmar JL. Hepatic metastases. Magn Reson Imaging Clin North Am. 1997;5:319-0.
  
• 作者单位：Luigi Grazioli (1) (5)
  Maria Pia Bondioni (1)
  Niccolò Faccioli (2)
  Sebastiana Gambarini (1)
  Rita Tinti (1)
  Günther Schneider (3)
  Miles Kirchin (4)
  
  1. Department of Radiology, University of Brescia, Brescia, Italy
  5. Department of Radiology, Azienda Ospedaliera, Spedali Civili di Brescia, 25123, Brescia, Italy
  2. Department of Radiology, University of Verona, Verona, Italy
  3. Department of Radiology, University of Homburg, Saarland, Germany
  4. Bracco Medical Imaging, Milan, Italy
  
• ISSN：1941-6636

文摘

Introduction The purpose of this paper is to illustrate contrast enhancement patterns of solid focal liver lesions on dynamic and late phase imaging with gadobenate dimeglumine (Gd-BOPTA). Imaging Findings Unenhanced T2- and T1-weighted, dynamic T1-weighted (arterial, portal-venous, and equilibrium) and late phase (1-3?h) Gd-BOPTA-enhanced MR imaging of different focal liver lesions (nodular regenerative hyperplasia, hepatic adenoma, liver adenomatosis, hepatocellular carcinoma, peripheral cholangiocarcinoma, hypervascular metastases, and hypovascular metastases) are shown. Dynamic imaging was performed using GRE T1-w sequences after the bolus injection of 0.1?mmol/kg Gd-BOPTA; late-phase imaging was obtained at 1-3?h after contrast injection. Conclusions Dynamic imaging with Gd-BOPTA provides the same information as with conventional gadolinium-based extracellular contrast agents, while late-phase imaging gives additional information for lesion identification and characterization.